Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study

Riveline, Jean‐Pierre; Roussel, Ronan; Vicaut, Éric; Pouvourville, Gérard de; Detournay, B.; Émery, C.; Levrat-Guillen, Fleur; Guerci, Bruno

doi:10.1089/dia.2022.0085

Cited by 33 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding hospital admissions, the findings of our study are in agreement with two observational studies 22,23 of T1D patients using isCGM that showed fewer admissions with DKA. One of these studies, 22 like our findings, reported no changes in the GOLD scores.…”

Section: Discussionsupporting

confidence: 92%

Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation

Ssemmondo,

Deshmukh,

Wilmot

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo understand the effect of intermittently scanned continuous glucose monitoring (isCGM) in people with diabetes with a ‘psychosocial’ indication for access.MethodsThe study utilized baseline and follow‐up data from the Association of British Clinical Diabetologists nationwide audit of people with diabetes in the UK. Diabetes‐related distress (DRD) was assessed using the two‐item diabetes‐related distress scale (DDS). Participants were categorized into two groups: high DRD (DDS score ≥ 3) and lower DRD (DDS score < 3). The t‐test was used to assess the difference in the pre‐ and post‐isCGM continuous variables.ResultsThe study consisted of 17 036 people with diabetes, with 1314 (7%) using isCGM for ‘psychosocial’ reasons. Follow‐up data were available for 327 participants, 322 (99%) of whom had type 1 diabetes with a median diabetes duration of 15 years; 75% (n = 241) had high levels of DRD. With the initiation of isCGM, after a mean follow‐up period of 6.9 months, there was a significant reduction in DDS score; 4 at baseline versus 2.5 at follow‐up (P < .001). The prevalence of high DRD reduced from 76% to 38% at follow‐up (50% reduction in DRD, P < .001). There was also a significant reduction in HbA1c (78.5 mmol/mol [9.3%] at baseline vs. 66.5 mmol/mol [8.2%] at follow‐up; P < .001). This group also experienced an 87% reduction in hospital admissions because of hyperglycaemia/diabetic ketoacidosis (P < .001).ConclusionPeople with diabetes who had isCGM initiated for a psychosocial indication had high levels of DRD and HbA1c, which improved with the use of isCGM.

show abstract

Section: Discussionsupporting

confidence: 92%

Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation

Ssemmondo,

Deshmukh,

Wilmot

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Bemerkenswert ist, dass die Anwendung von CGM bei Menschen mit Typ-2-Diabetes, die mit Basalinsulin behandelt werden, über eine Verbesserung der Glukosekontrolle hinaus auch mit einer signifikanten Reduktion von Endpunkten wie Krankenhauseinweisungen aufgrund von diabetischer Ketoazidose (DKA) oder schwerer Hypoglykämie (SH) verbunden ist [36,37,38,40,41] (▶ Tab. 2).…”

Section: Einsatz Von Cgm Bei Basalunterstützter Oraler Therapie (Bot)unclassified

Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung

Seufert,

Dänschel,

Gölz

et al. 2024

Diabetologie und Stoffwechsel

View full text Add to dashboard Cite

ZusammenfassungZahlreiche Studien haben den klinischen Nutzen der kontinuierlichen Glukosemessung (CGM) bei Menschen mit Typ-1-Diabetes belegt, was auch zu einer positiven Empfehlung des Gemeinsamen Bundesausschusses (GBA) für CGM-Systeme bei Menschen mit Diabetes und intensivierter Insulintherapie (ICT/Insulinpumpentherapie) geführt hat. Inzwischen liegen die Ergebnisse zahlreicher randomisierter, beobachtender und retrospektiver Studien zum Einsatz von CGM bei Menschen mit Typ-2-Diabetes und einer nicht intensivierten Insulintherapie (BOT/SIT/CT) oder einer Therapie ohne Insulin vor. In diesem Artikel wird die aktuelle Evidenz zum Einsatz von CGM bei diesen Patientengruppen zusammengefasst und diskutiert. Die Ergebnisse dieser Studien deuten darauf hin, dass CGM auch bei Menschen ohne intensivierte Insulintherapie wirksam ist, um die glykämische Kontrolle zu verbessern und mögliche Nebenwirkungen der Insulintherapie (Hypoglykämien) zu vermeiden.

show abstract

“…The benefits of continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2DM) have recently been documented in populations receiving basal insulin only, 1 basal-bolus therapy 2,3 and even in patients not receiving insulin. 4,5 The use of CGM in T2DM reduced acute diabetes complications in epidemiological studies [6][7][8][9][10] and had the potential to improve quality of life and diabetesrelated complications while reducing long-term healthcare costs. 11,12 The current clinical guidelines of the National Institute for Health and Care Excellence (NICE) recommend CGM to adults with type 2 diabetes on multiple daily insulin injections if one of the following applies: 1.…”

Section: Introductionmentioning

confidence: 99%

An estimate of the need for continuous glucose monitoring in type 2 diabetes with intensive insulin treatment in secondary healthcare

Trolle,

Christensen,

Hansen

2024

Diabet Med

View full text Add to dashboard Cite

AimTo estimate the proportion of persons with type 2 diabetes (T2DM) receiving intensive insulin treatment in the secondary healthcare who could be candidates for continuous glucose monitoring (CGM), based on different HbA1c criteria. For comparison, the results are also presented as proportion of persons with type 1 diabetes (T1DM) in the same region.Patients and MethodsIn the Central Denmark Region, we identified all persons with T1DM (n = 6179) and T2DM (n = 4315) who had a minimum of one contact to a diabetes outpatient clinic from September 2021 to September 2022. Insulin regimen and HbA1c measured after a minimum of 2 months with a stable insulin regimen were retrieved from the healthcare administrative electronic platform used in the region.ResultsThe numbers of persons with T1DM and T2DM with HbA1c meeting the criteria were 5145 and 3090, respectively. The fraction of T2DM with basal‐bolus insulin was 35.3%, and the fraction with basal‐bolus insulin and HbA1c >53 (7%) mmol/mol or >58 (7.5%) mmol/mol was 20.5% and 16.6%, respectively. These proportions correspond to 19.4%, 14.4% and 11.7% of the persons with T1DM in the same geographical area.ConclusionThe proportion of persons with T2DM in secondary healthcare undergoing intensive insulin treatment who could be candidates for CGM corresponded to only a minor fraction of persons with T1DM in the same region, irrespective of any HbA1c criteria applied.

show abstract

Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study

Cited by 33 publications

References 32 publications

Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation

Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation

Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung

An estimate of the need for continuous glucose monitoring in type 2 diabetes with intensive insulin treatment in secondary healthcare

Contact Info

Product

Resources

About